Check the time stamp on this data. Updated AI-Generated Signals for Crispr Therapeutics Ag (CRSP) available here: CRSP.

Value outperformed in 2022, with the Russell 1000 Value index falling about 7.5 percent compared to a more than 29 percent decline for the Russell 1000 Growth index. But that tren ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) was upgraded by analysts at StockNews.com to a “sell” rating in a ...

Bullish option flow detected in Crispr Therapeutics (CRSP) with 3,137 calls trading, 1.3x expected, and implied vol increasing almost 2 points ...

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where ...

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report)’s stock price reached a new 52-week low during mid-day trading on ...

Read about how Crispr's robust pipeline for cardiovascular diseases holds blockbuster potential, with top-line results ...

We recently compiled a list of the 10 Best Gene Therapy Stocks to Buy Right Now. In this article, we are going to take a look ...

Crispr Therapeutics AG (CRSP) stock saw a decline, ending the day at $40.02 which represents a decrease of $-1.05 or -2.56% from the prior close of $41.07. The stock opened at $40.76 and touched a low ...

I maintain a buy rating on VB due to its reasonable valuation, solid earnings growth, and bullish chart, despite a recent 10% ...

Conditions are favorable for these seven small-cap ETFs that have strong growth momentum entering 2025.

And despite major regulatory wins since late 2023, the biotech hasn't recovered: The stock is down 23% year to date. Can CRISPR Therapeutics bounce back? Some recent developments could move the needle ...